Post-Conference Perspectives: ASCO GU 2021

Neal Shore, MD, discusses the recent FDA approval of the first oral GNRH receptor antagonist, relugolix, for men with advanced prostate cancer, along with data from the phase 3 HERO trial.

Dan George, MD, reviews new findings in advanced prostate cancer presented at ASCO GU 2021.

Stephen Freedland, MD, discusses risk factors involved in men with advanced prostate cancer who receive androgen deprivation therapy.

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.